[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Joe [@Gantosj](/creator/twitter/Gantosj) on x 13.3K followers Created: 2025-07-22 13:53:13 UTC $CRDL’s current valuation barely reflects the significant progress in its #pericarditis program, which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive, the stock could see a rapid re-rating to the upside. The Ph-3 trial for recurrent pericarditis is considered highly de-risked, thanks to the robust results from the earlier open-label Ph-2 study, which closely mirrors the approach used by an already approved IL-1 blocker. XXXXX engagements  **Related Topics** [robust](/topic/robust) [$crdls](/topic/$crdls) [Post Link](https://x.com/Gantosj/status/1947656179842162968)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Joe @Gantosj on x 13.3K followers
Created: 2025-07-22 13:53:13 UTC
$CRDL’s current valuation barely reflects the significant progress in its #pericarditis program, which has already advanced to Ph-3. If the upcoming Ph-2 #myocarditis data turns out positive, the stock could see a rapid re-rating to the upside.
The Ph-3 trial for recurrent pericarditis is considered highly de-risked, thanks to the robust results from the earlier open-label Ph-2 study, which closely mirrors the approach used by an already approved IL-1 blocker.
XXXXX engagements
